Unterzeichnung(en)
Übersicht
European R&D site(s) of the promoter.
The project comprises the promoter’s ongoing R&D programme 2007-2009 and includes expenditures incurred in the promoter’s European facilities for internal personnel and other operating costs as well as expenses for clinical trials, cooperation, licences, patent registration and laboratory equipment.
RDI activities will not materially change current RDI practice and will be carried out within existing facilities, making use of existing laboratories, pilot plants, clinical centres, etc. An EIA therefore is not required by EU Directive 97/11.
The promoter is a private company not operating in the Utilities sector, and is thus not covered by EU Directives on procurement.
This RDI project, encompassing leading R&D in biopharmaceutical and in medical devices aims at the development of innovative therapies and products targeting life-threatening diseases.